SCHEMBL2305783

SCHEMBL2305783

O=C(Nc1nc2c(s1)CCc1ccccc1-2)c1ccc(Cl)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.61
MAPT P10636 8/20 0.61
KMT2A Q03164 5/20 0.61
LMNA P02545 4/20 0.61
MEN1 O00255 4/20 0.61
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
NPSR1 Q6W5P4 2/20 0.61
USP2 O75604 1/20 0.61
HTT P42858 1/20 0.61
SMN1; SMN2 Q16637 5/20 0.60
ALDH1A1 P00352 3/20 0.60
HSD17B10 Q99714 1/20 0.60
KDM4E B2RXH2 5/20 0.58
HPGD P15428 2/20 0.58
XIAP P98170 1/20 0.56
ALOX5 P09917 1/20 0.55
TP53 P04637 4/20 0.55
RXFP1 Q9HBX9 1/20 0.55
CYP1A2 P05177 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957325 0.82 MAPT (0.71) POLBMAPTKMT2ALMNAMEN1
SCHEMBL3310614 0.81 MAPT (0.55) POLBMAPTKMT2ALMNAMEN1
SCHEMBL4963803 0.79 MAPT (0.67) POLBMAPTKMT2ALMNAMEN1
SCHEMBL3311847 0.79 KDM4E (0.68) POLBMAPTKMT2ALMNAMEN1
SCHEMBL4960420 0.77 MAPT (0.64) POLBMAPTKMT2ALMNAMEN1
SCHEMBL1822988 0.76 MAPT (0.70) POLBMAPTKMT2ALMNAMEN1
SCHEMBL1813074 0.76 MAPT (0.63) POLBMAPTKMT2ALMNAMEN1
SCHEMBL2363366 0.75 TBK1 (0.52) POLBMAPTKMT2ALMNAMEN1
SCHEMBL24090371 0.75 SMN1; SMN2 (0.66) POLBMAPTKMT2ALMNAMEN1
SCHEMBL4957466 0.74 POLB (0.61) POLBMAPTKMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
CN-102203280-A Diacylglycerol acyltransferase inhibitors VIA PHARMACEUTICALS INC 2011-09-28 CN disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 POLB 3823/4885MAPT 4008/4885KMT2A 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.